Overview

Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and immunosuppression. In this study, spleen irradiation (SI) will be added to standard chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital

Collaborator:

PharmaEngine, Inc.

Treatments:

Irinotecan
Leucovorin